[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophreniform-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophreniform-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,72,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100371255","phase-4-bazedoxifene--treatment-for-women-with-schizophrenia-100371255",false,"NCT04113993","Bazedoxifene -Treatment for Women With Schizophrenia","Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial","Inclusion Criteria:\n\n* Physically well.\n* A current DSM-V diagnosis of schizophrenia or related disorder.\n* 18- 65 years\n* Able to give informed consent.\n* PANSS total score between 40 and 90.\n* Documented normal PAP smear and pelvic examination in the preceding two years.\n* Stable psychotropic medication for previous 4 weeks\n* Normal breast screen (for women aged over 40 years)\n* IQ \\> 70 (as determined by the WAIS IV subtests)\n* English language proficiency (in order to provide informed consent and complete cognitive test battery)\n\nExclusion Criteria:\n\n* Patients with known abnormalities in the hypothalamo-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event.\n* Patients with a history of severe traumatic brain injury or significant neurological or unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; presence of illness causing immobilisation.\n* Patients whose psychotic illness is directly related to illicit substance use or who have a history of substance dependence during the last six months (with the exclusion of caffeine and\u002For nicotine dependence).\n* Women aged 40 or over who have not had a normal mammogram in the last 24 months\n* Use of any form of estrogen, progestin or androgen as hormonal therapy in preceding 4 weeks including the pill (excluding IUD or Hormone Implants).\n* Pregnant (HCG will be measured at screening)\n* Breastfeeding\n* Planned changes to psychotropic medication or psychotherapy regimen.","FEMALE","18 Years","65 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","To study the effect of adjunctive bazedoxifene - a selective estrogen receptor modulator (SERM) in a double blind, placebo-controlled adjunctive study in the treatment of women with schizophrenia. All patients receive standardized antipsychotic medication.",[27,28,29],"Schizophrenia","Schizophreniform Disorders","Schizo Affective Disorder","RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-03","ACTUAL",{"date":36,"type":34},"2019-10-07",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"The Alfred","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100593476","reach-study-recovery-environments-assessing-cognitive--brain-health-in-community-mental-health-100593476","NCT07006935","REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)","Pilot Study of the Cognitive and Neurobiological Effects of the Clubhouse Model of Psychosocial Rehabilitation for Schizophrenia and Related Conditions","Inclusion Criteria:\n\n* (1) have a DSM-V diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform confirmed by diagnostic assessment and medical record review\n* (2) between the ages of 18-50\n* (3) stabilized on psychotropic medication as indicated by no changes to the primary psychiatric medication in the last month\n* (4) able to read and speak fluent English at a sixth grade level or higher for purposes of informed consent and cognitive testing\n* For Clubhouse members, they must be a first-time, newly enrolled member\n\nExclusion Criteria:\n\n* (1) had previous membership at a Clubhouse (Magnolia or elsewhere)\n* (2) have a current severe substance use disorder\n* (3) have persistent suicidal or homicidal behavior\n* (4) a co-occurring diagnosis of an intellectual or learning disability or neurodevelopment condition (e.g., Autism; based on chart review)\n* (5) had recent psychiatric instability requiring hospitalization in the past month;\n* (6) history of a traumatic brain injury (TBI; based on record review)\n* (7) contraindicators for MRI (e.g., pacemaker, claustrophobia)\n* Participants in the usual care will be excluded if they are a current Clubhouse member or join a Clubhouse during participation in this research","ALL","50 Years",{"count":53,"type":21},30,[55],"NA","The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Model-a structured, supportive community for individuals with mental illness-has unique benefits compared to standard outpatient mental health services. If participants decide to join, they will be asked to complete a total of six study visits with the research team over the course of your participation. Three of these study visits are at the beginning (baseline) and the remaining three are six months later. Two of the three visits will includes interviews, questionnaires, and thinking and memory tasks (cognitive testing) and one session will be an MRI brain scan, which is a safe and non-invasive imaging procedure. The total time required for each visit will be approximately 90 minutes to two hours. Participants may take breaks as needed.",[27,29,28],[59,60,61,62],"Clubhouse Model of Psychosocial Rehabilitation","Community mental health interventions","Cognition","Brain functioning","NOT_YET_RECRUITING","2026-04-24",{"date":66,"type":34},"2026-04-27",{"date":31,"type":21},{"date":69,"type":21},"2028-01-30",{"name":71,"class":41},"Case Western Reserve University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100471268","shared-decision-making-for-antipsychotic-medications-100471268","NCT05416658","Shared Decision Making for Antipsychotic Medications","Examining the Effectiveness of a Shared Decision Making Intervention for Antipsychotic Medications to Improve Engagement in Treatment for People Experiencing Early Psychosis","Inclusion Criteria:\n\n* Ages 18 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified\u002Funspecified schizophrenia spectrum and other psychotic disorders (ICD-10-CM Diagnosis Code F20.x)\n* Current\u002Fpast experiences with antipsychotic medications (APM; e.g., currently taking any antipsychotic medication, stopped taking, or considering stopping).\n* Receive FEP treatment in one of OnTrackNY clinics\u002Fsites randomized to intervention or treatment as usual (TAU) - Willing to participate in research interviews after each APM visit during the study period (3 months)\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* No experience with APM\n* Not fluent (speaking, reading, writing) in English","30 Years",{"count":81,"type":21},120,[55],"This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the first time, an understanding of the shared decision making mechanism of action.",[27,85,28,86,87],"Schizoaffective Disorder","Delusional Disorder","Other Specified Schizophrenia Spectrum and Other Psychotic Disorder",[89,90,91,92,93,94,95,96,97],"Shared decision making","psychosis","schizophrenia","antipsychotic","medication","intervention","decision aid","coordinated specialty care (CSC)","randomized controlled trial (RCT)","2026-03-24",{"date":100,"type":34},"2026-03-30",{"date":102,"type":21},"2027-01-01",{"date":104,"type":21},"2027-06-30",{"name":106,"class":41},"New York State Psychiatric Institute",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":42},"100525171","itbs-to-enhance-social-cognition-in-people-with-psychosis-100525171","NCT06118268","iTBS to Enhance Social Cognition in People With Psychosis","iSCIP","Inclusion Criteria:\n\n1. Age 18-39 years.\n2. DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychotic disorder not otherwise specified (documented by SCID-5).\n3. Prescription of antipsychotic medication for at least 60 days and constant dose for 30 days prior to study entry (either first- or second-generation antipsychotics permitted).\n4. Able to participate in the informed consent process and provide voluntary informed consent.\n\nExclusion Criteria:\n\n1. A history of a DSM-5 substance use disorder (other than cannabis, caffeine, or tobacco) within the past six months; or a positive baseline urine drug screen. Only participants meeting for moderate to severe cannabis use disorder will be excluded.\n2. Type 1 diabetes mellitus (i.e., insulin-dependent diabetes mellitus with onset \\\u003C 35 years of age and\u002For diabetes mellitus that has been complicated by a prior documented episode of ketoacidosis)\n3. Acute or unstable medical illness (e.g., delirium, cancer, uncontrolled diabetes, decompensated cardiac, hepatic, renal or pulmonary disease, stroke, or myocardial infarction), whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol\n4. Neurological disease associated with extrapyramidal signs and symptoms (e.g., Parkinson's disease); epilepsy, if the person has had one or more grand mal seizures in the past 18 months; history or physical signs of stroke; any diagnosis of a Central Nervous System (CNS) disorder\n5. Requires a benzodiazepine with a dose equivalent to lorazepam 2 mg\u002Fday or higher due to the potential of these medications to limit the efficacy of iTBS\n6. Suspected DSM-5 intellectual disability based upon clinical interview and psychosocial history\n7. Prior Psychosurgery\n8. Presence of MRI contraindications (e.g., pacemakers)\n9. Pregnancy\n10. TMS treatment in the past three months","39 Years",{"count":116,"type":21},100,[55],"The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychotic disorder not otherwise specified. The main objectives of this trial are:\n\n* Compare changes in social cognitive performance between the active vs. sham treatment groups\n* Compare changes in social cognitive network functional connectivity between the active vs. sham treatment groups\n\nEach participant will receive iTBS (active or sham) five days per week for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at pre-treatment, post-treatment, and 6 months after the completion of treatment.",[27,29,28,120],"Psychosis Nos\u002FOther",[122,123],"TMS","iTBS","2025-05-19",{"date":126,"type":34},"2025-05-22",{"date":128,"type":34},"2023-04-18",{"date":130,"type":21},"2027-04",{"name":132,"class":41},"Northwell Health"]